How This Actually Works, Step by Step

Most international patients assume the first step is a plane ticket. It isn’t. The sequence that saves the most time and money looks like this.

Step one: gather your records. You’ll need pathology reports with Gleason scores, PSA history over time, imaging (PSMA PET-CT, bone scans, MRI), and a clear list of every hormone therapy and chemotherapy you’ve already tried, with dates and responses. This is the file that determines everything downstream.

Step two: get a written second opinion. You send those records to us, we route them to the relevant Chinese specialty team, and they return a written analysis with treatment suggestions and direction. Turnaround is typically five to ten business days, and it costs $300–500. Nothing is prescribed at this stage — the document is for reference and decision-making, not a prescription.

Step three: speak with the team directly. A video consultation lets you explain your symptoms and goals while the Chinese physicians walk you through their recommendations. Standard international-department sessions run $100–300; a top-specialist session runs $500–800. If your case is complex, a multidisciplinary team review with urology, oncology, and radiation oncology together is $1,500–2,000.

Step four: decide whether to travel. Only after a feasible plan is on the table does coming to Shanghai make sense. At that point we coordinate hospital communication, arrival support, and available green-channel logistics. Admission itself always remains subject to hospital rules — nobody can promise a bed in advance, and anyone who does is not being straight with you.

What Treatment Options Exist for Hormone-Resistant Prostate Cancer in Shanghai

Castration-resistant prostate cancer — the term most Chinese urology departments use — sits at the intersection of several specialties. Shanghai’s large academic centers typically approach it through a combination of systemic therapy, targeted radiation, and sometimes surgery for oligometastatic disease.

On the systemic side, expect the standard global arsenal: docetaxel and cabazitaxel chemotherapy, androgen-receptor pathway inhibitors such as abiraterone and enzalutamide, and where eligible, PARP inhibitors for patients with BRCA or other homologous recombination repair mutations. Lu-177 PSMA radioligand therapy, which has drawn considerable international attention, is available at selected high-volume centers in China, though availability and eligibility criteria vary by institution and are subject to regulatory approval status. We do not claim universal access to any specific agent — that has to be confirmed hospital by hospital, and we verify it case by case.

Radiation oncology matters here too. For men with a limited number of metastatic sites, stereotactic body radiotherapy to those lesions can delay progression. Shanghai’s academic centers have invested heavily in this area, and prostate-specific membrane antigen PET imaging is now routine at the larger facilities, which changes how precisely lesions can be targeted.

Where does surgery fit? Cytoreductive prostatectomy for metastatic disease remains controversial worldwide, and Chinese surgeons are no exception in their caution. Some high-volume centers will consider it in carefully selected patients. Most will not. That honest split is worth knowing before you build expectations around it.

A Realistic Timeline

People underestimate the paperwork phase and overestimate how fast a hospital slot appears. Here’s what the calendar usually looks like.

Add buffer. Chinese public hospitals do not allow overseas patients to pre-book an ordinary outpatient slot from abroad — registration typically happens on the day, which is exactly why international-department or VIP channels exist. Those channels cost roughly 1.5 to 2 times the standard fee and come with English-speaking staff and more predictable scheduling.

What Can Go Wrong — and What Happens Then

The failure modes here are specific, and pretending they don’t exist would be dishonest.

The hospital declines the case. This happens. Some patients arrive having already failed every approved line of therapy, and the Chinese team concludes that further systemic treatment offers more harm than benefit. You’d get that answer in writing during the second-opinion stage rather than after a 14-hour flight, which is the entire point of doing remote evaluation first.

The drug you want isn’t available at your chosen hospital. Availability of newer agents varies between institutions. The recourse is straightforward: we check with alternative hospitals before you commit, and the plan adjusts. It’s inconvenient, not catastrophic.

The visa is delayed. S2 applications require supporting documents from the treating hospital, and consulate requirements change. We provide guidance, but we cannot guarantee approval — no service can. Build two to three weeks of slack into your timeline.

You arrive and the specialist is unavailable. Senior physicians travel, operate, and teach. If a coordinated appointment can’t be secured, our appointment coordination fee is refunded in full. That’s the standard we hold ourselves to.

Complications during treatment. This is the one nobody wants to discuss. Prostate cancer therapies carry real risks — neutropenia, neuropathy, fatigue, radiation toxicity. Chinese tertiary hospitals manage these routinely, and you’ll be in a facility with full intensive care capability. But you should also have a clear plan for follow-up care once you return home, and we’ll say so plainly.

How to Choose Among Shanghai’s Prostate Cancer Programs

Shanghai has more than one credible option, and the right choice depends on your specific situation rather than a generic ranking.

Start with the Fudan specialty reputation rankings. These list the top 10 hospitals nationally for each of 45 specialties, including oncology and urology, and they’re a more useful signal than any overall hospital position. A hospital ranked among China’s top 10 for oncology is a reasonable starting filter. You can browse specialty-level listings on our departments directory.

Then consider volume. Prostate cancer outcomes correlate with how many cases a center handles, and Shanghai’s academic hospitals are high-volume by any global standard. Ask directly: how many castration-resistant cases does this department treat annually? A team that hesitates on that question is telling you something.

Third, weigh the practical layer. Public tertiary hospitals are enormous — some see over 10,000 outpatient visits a day — and navigation without Mandarin is genuinely difficult. Private international hospitals such as United Family, Jiahui, and Parkway offer English-speaking staff, JCI accreditation, and direct insurance billing, but they are not where the deepest prostate cancer subspecialty expertise usually sits. Many patients use a hybrid: academic hospital for the treatment plan, private facility for some supportive care.

Fourth, look at clinical trial access. Several Shanghai centers run investigator-initiated studies in advanced prostate cancer. If you’ve exhausted standard options, this can matter more than anything else on this list. Our hospital database covering 340+ top-ranked hospitals across 37 cities lets you filter by city and specialty before you commit to anything.

Practical Considerations: Records, Visas, Money, and Follow-Up

Records. Bring originals plus certified translations. Chinese physicians read English, but pathology and imaging reports are far easier to review in Chinese, and translation errors in a Gleason score are not a small problem.

Visa. Medical travel to China uses the S2 visa, which covers short stays for medical treatment and private affairs, with supporting documents from the hospital. Stays beyond 180 days fall under S1. Accompanying family members apply for S2 as well. Note clearly: the M visa is for commercial and trade activities and has nothing to do with medical treatment. Requirements shift, so confirm current rules with the nearest Chinese embassy or consulate.

Payment. Public hospitals generally require prepayment, with insurance reimbursement handled afterward in your home country. Private international hospitals often bill insurers directly. Budget for the possibility that your insurer will reimburse at out-of-network rates.

Cost. Advanced prostate cancer treatment in China typically runs well below US pricing, though exact figures depend heavily on the regimen. A bilingual medical companion costs from $300 per day, airport transfers run $200 round-trip, and hospital appointment coordination starts at $300.

Follow-up. Arrange your home oncology team’s involvement before you leave. Continuity of care matters more than any single treatment cycle.

Frequently Asked Questions